FY2025 · ended Dec 31, 2025 · Revenue $17.44M, +16.0% YoY · Filed Apr 15, 2026
Vivos Therapeutics, Inc. (VVOS) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $17.4 million and a net loss of $21.2 million. Free cash flow was -$17.6 million. As of Jun 30, 2026 it held $1.8 million in cash and investments and $12.5 million in total debt.
Revenue (TTM)
$20.90M
+45.2% vs year-ago TTM
Net income (TTM)
$-25.46M
-77.8% vs year-ago TTM
Operating cash flow (TTM)
$-17.13M
-18.8% vs year-ago TTM
Free cash flow (TTM)
$-19.01M
-21.4% vs year-ago TTM
EPS (TTM)
$-1.84
-3.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
13.49M
+129.0% vs prior year
Net cash
$-10.73M
as of Jun 30, 2026
Operating margin
-107.9%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- VVOS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Littleton, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1716166
- Former names
- Vivos BioTechnologies, Inc. (until Sep 29, 2017)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M |
| Operating income | -$19.9M | -$11.2M | -$17.3M | -$25.0M | -$20.4M |
| Net income | -$21.2M | -$11.1M | -$13.6M | -$23.8M | -$20.3M |
| Diluted EPS | -$2.07 | -$2.22 | -$11.14 | — | — |
| Operating cash flow | -$15.3M | -$12.7M | -$11.9M | -$19.6M | -$15.7M |
| Free cash flow | -$17.6M | -$13.3M | -$12.7M | -$20.5M | -$18.1M |
| Total assets | $25.2M | $15.3M | $10.7M | $13.7M | $33.7M |
| Total liabilities | $26.7M | $7.3M | $10.3M | $8.9M | $8.2M |
| Stockholders' equity | -$1.5M | $8.0M | $411,000 | $4.8M | $25.5M |
| Cash and investments | $2.0M | $6.3M | $1.6M | $3.5M | $24.0M |
| Total debt | $13.5M | $2.7M | $3.2M | $2.4M | $1.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 21, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Oct 19, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Auditor change
|
Oct 1, 2026 | Sep 29, 2026 |
| 8-K/A |
Amended current report
Material agreement, Unregistered share sale
|
Sep 8, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 8, 2026 | Aug 31, 2026 |
All 301 Vivos Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.